The Efficacy and Safety of Ivabradine Tablet in Patients with heart failure
- Conditions
- Health Condition 1: I502- Systolic (congestive) heart failure
- Registration Number
- CTRI/2018/04/013464
- Lead Sponsor
- Abbott Healthcare Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 180
1.Male and female between 18 to 70 years (both inclusive)
2.Currently receiving stable dose of Ivabradine IR 5 mg /7.5 mg BID since >= 1 month for stable chronic HF with systolic dysfunction
3.Concurrently receiving standard care for stable CHF (as per recommendation 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic HF)8
4.Documented stable chronic CHF of NYHA Class II to III >= 6 weeks at the time of screening
5.Sinus rhythm with clinically stable HR >50 bpm (both inclusive) as assessed automatically by a standard 12-lead ECG
6.Documented LVEF <=40 % at screening
7.No physical limitation to ingest and retain oral medication
8.Willingness to participate in the study and provide written informed consent
1.History of recent MI, coronary revascularization, stroke, or transient ischemic attack <= 3 months), or with a transplanted heart, implanted pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy
2.Scheduled for coronary revascularization, or likely to require surgery for valvular disease during the study period
3.Permanent atrial fibrillation or flutter or any other cardiac arrhythmias which may interfere with function of sinoatrial node
4.Sick sinus syndrome, sinoatrial block, congenital long QT or treated with QT prolonging medications, 2nd degree and complete atrioventricular block
5.Stroke or transient cerebral ischemia within previous <= 3 months prior at screening
6.Unstable or acute HF, unstable angina
7.Severe or uncontrolled hypertension (systolic BP [SBP] >= 190 mmHg or diastolic BP [DBP] >= 110 mmHg) uncontrolled hypotension (SBP <= 90 mmHg or DBP <= 50 mmHg)
8.History of frequent hypoglycemia within <=3 months at screening
9.Hospitalization for worsening HF (NYHA class II or higher) <= 3 months at screening
10.Any cardiac condition which does not justify the inclusion of the patient in the study as per investigator discretion (e.g. severe primary valvular disease, active myocarditis, congenital heart disease, peripartum cardiomyopathy, etc.)
11.Patient having the following laboratory results at screening:
a.Hemoglobin (Hb) men <11 g/dL, women <10 g/dL
b.ALT/AST levels >= 3 Ñ? ULN
c.eGFR <15 mL/min
12.Women who are, pregnant, nursing, or planning to become pregnant or who are of childbearing potential not willing to implement appropriate contraceptive measures or who are considering to stop appropriate use of contraception during the study period
13.Contraindication to Ivabradine or its excipients; or Ivabradine not recommended or known to be not effective, or requirement for a not recommended concomitant treatment (as per Procoralan�Ivabradine prescribing information and SPC of Procoralan®)
14.History of psychiatric disorders which may interfere with patientâ??s ability to understand or complete requirements of the study
15.Any other illness or conditions that does not justify patientâ??s participation in the study as judged by the investigator (E.g. Alcohol abuse, chronic illness like memory loss, Alzheimerâ??s etc)
16.Is currently participating in any other clinical trial or has participated in any other clinical trial 3 months prior to screening
17.Not willing to comply with all aspects of the protocol
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare change in resting HR from baseline to end of 3 months between Ivabradine PR and Ivabradine IR tablets as assessed by taking 3 consecutive ECGs within 30 minutes by automated standard 12lead ECGTimepoint: Baseline to end of 03 month
- Secondary Outcome Measures
Name Time Method Treatment emergent adverse events (TEAEs) during the study (including nature, severity, and frequencyTimepoint: 03 Month